Table 1. Patient demographics.
| EA (n = 165) | Non-EA (n = 834) | p | |
|---|---|---|---|
| Age, year | 65 ± 13 | 65 ± 14 | 0.889 |
| Sex, male | 112 (67.9%) | 500 (60.0%) | 0.056 |
| BMI, kg·m-2 | 23.7 ± 3.9 | 23.0 ± 3.5 | 0.080 |
| ASA ≥ 3 | 60 (36.4%) | 327 (39.2%) | 0.493 |
| Comorbidites | |||
| Diabetes | 33 (20.0%) | 170 (20.4%) | 0.911 |
| Coronary artery disease | 11 (6.7%) | 61 (7.3%) | 0.769 |
| Heart failure | 10 (6.1%) | 34 (4.1%) | 0.256 |
| Stroke | 9 (5.5%) | 48 (5.8%) | 0.879 |
| Chronic kidney disease | 15 (9.1%) | 123 (14.7%) | 0.054 |
| Pretreatment CEA, μg·L-1 | 19.7 (3.5–82.8) | 18.4 (4.1–92.0) | 0.632 |
| Tumor location | 0.270 | ||
| Right-sided colon | 48 (29.1%) | 265 (31.8%) | |
| Left-sided colon | 61 (37.0%) | 338 (40.5%) | |
| Rectum | 56 (33.9%) | 231 (27.7%) | |
| Anesthesia time, min | 300 (255–390) | 315 (255–390) | 0.567 |
| pRBC transfusion | 0.350 | ||
| No transfusion | 101 (61.2%) | 476 (57.1%) | |
| ≦4 units | 46 (27.9%) | 259 (31.1%) | |
| > 4 units | 18 (10.9%) | 99 (11.9%) | |
| Preoperative C/T ± R/T | 15 (9.1%) | 140 (16.8%) | 0.013 |
| Postoperative C/T (< 90 days) | 0.002 | ||
| Nil | 13 (7.9%) | 97 (11.6%) | |
| Pure C/T | 89 (53.9%) | 328 (39.3%) | |
| C/T + TT | 63 (38.2%) | 409 (49.0%) | |
| Postoperative R/T (< 90 days) | 24 (14.5%) | 86 (10.3%) | 0.112 |
| Follow-up time, months | 18.3 (6.8–35.5) | 17.4 (7.6–31.0) | 0.370 |
Values were mean ± SD, counts (percent), or median (interquartile range). Continuous variables are analyzed with Wilcoxon rank-sum tests; categorical variables are analyzed with Pearson chi-square tests or Mann-Whitney U tests, as appropriate. BMI: body mass index; ASA physical status: American Society of Anesthesiologists physical status; CEA: carcinoembryonic antigen; pRBC: packed red blood cell; C/T: chemotherapy; TT: target therapy; R/T: radiotherapy.